Drug Safety Concerns Create CRO Opportunity, PPD Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Contract research organizations could see financial opportunities in "more intricate safety monitoring," CEO Eshelman says during earnings call. Regulatory uncertainty accompanies shift in PPD's business away from big pharma, toward biotech firms.